PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 13, 2026Journal of Experimental & Clinical Cancer Research0 citationsOpen Access

Unbiased profiling of translational landscape reveals TNFR2 as a translation-dependent vulnerability in colorectal cancer

YCYiying ChenYGYufeng GaoHWHaixia Wang

Key Points

  • The aim is to characterize translational vulnerabilities in colorectal cancer (CRC) and identify key regulatory mechanisms.
  • Profiled 34 colorectal tissue samples to assess the translatomic landscape.
  • Identified unannotated open reading frames and long noncoding RNAs.
  • Characterized translatomic clusters related to clinical features and mutations.
  • Analyzed a network of genes regulated at the translational level and their role in CRC progression.
  • Validated TNFR2 inhibition in cell-based and organoid models, and in patient-derived organoid xenograft models.
  • Identified a coherent network of 449 genes that regulate CRC progression at the translational level.
  • Highlighted TNFR2 as a significant target with increased translational activation in CRC.
  • Demonstrated that pharmacological inhibition of TNFR2 significantly suppressed tumorigenesis in multiple models.
  • Established a systematic framework linking translatomic discovery and functional validation.

Abstract

Translational dysregulation plays a key role in tumour initiation and progression, including in colorectal cancer (CRC). However, the mechanisms underlying translational control and the systematic characterization of translation-dependent vulnerabilities remain poorly understood in CRC. We profiled 34 colorectal tissue samples to define a comprehensive translatomic landscape of CRC, uncovering a set of unannotated ORFs from coding (both in-frame and out-of-frame) and long noncoding RNAs (lncRNAs). Additionally, we delineated five translatomic clusters that significantly correlated with specific clinical features and common CRC mutations. Further analysis revealed a functionally coherent network of 449 genes that are exclusively regulated at the translational level and specifically promote CRC progression by modulating cell growth and immune responses. Among these, tumour necrosis factor receptor 2 (TNFR2) stood out as the most promising vulnerability with significant translational activation in CRC. Pharmacological inhibition of TNFR2 suppressed tumorigenesis in both cell-based and organoid models, and was further validated in vivo using patient-derived organoid xenograft (PDOX) models. Our study establishes a systematic framework bridging unbiased translatome discovery to functional validation, in which we identified and functionally validated the therapeutic vulnerability of translationally activated TNFR2 in CRC.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/69dc88f43afacbeac03eabb9https://doi.org/10.1186/s13046-026-03706-6
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer2017 · 81 citations
  2. 2Comprehensive molecular characterization of human colon and rectal cancer2012 · 8,791 citations
  3. 3Inhibiting CD164 Expression in Colon Cancer Cell Line HCT116 Leads to Reduced Cancer Cell Proliferation, Mobility, and Metastasis in vitro and in vivo2012 · 44 citations
  4. 4Expression of EZH2 is associated with poor outcome in colorectal cancer2017 · 41 citations
  5. 5Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target2019 · 181 citations